Risk of oral and gastrointestinal mucosal injury in patients with solid tumors treated with everolimus, temsirolimus or ridaforolimus: a comparative systematic review and meta-analysis

References

• Humar R, Kiefer FN, Berns H, et al. Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin [mTOR]-dependent signaling. FASEB J 2002;16:771-80
   PubMed Web of Science ®Google Scholar
• Lane HA, Breuleux M. Optimal targeting of the mTORC1 kinase in human cancer. Curr Opin Cell Biol 2009;21:219-29
   PubMed Web of Science ®Google Scholar
• Yao JC, Phan AT, Chang DZ, et al. Efficacy of RAD001 [everolimus] and octreotide LAR in advanced low-to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol 2008;26(26):4311-18
   PubMed Web of Science ®Google Scholar
• Peterson ME. Management of adverse events in patients with hormone receptor-positive breast cancer treated with everolimus: observations from a phase III clinical trial. Support Care Cancer 2013;21(8):2341-9
   PubMed Web of Science ®Google Scholar
• Panzuto F, Rinzivillo M, Fazio N, et al. Real-World Study of Everolimus in Advanced Progressive Neuroendocrine Tumors. Oncologist 2014;19(9):966-74
   PubMed Web of Science ®Google Scholar
• Yardley DA. Adverse event management of mTOR inhibitors during treatment of hormone receptor–positive advanced breast cancer: considerations for oncologists. Clin Breast Cancer 2014;14(5):297-308
   PubMed Web of Science ®Google Scholar
• Afinitor [Everolimus] tablets for mucocutaneous administration [summary of product characteristics] Stein. Novartis Pharma AG, Switzerland; 2012. Available from: http://www.medicines.org.uk/emc/medicine/22281/SPC/Afinitor+Tablets [Last accessed 8 May 2015]
   Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009;62(10):1006-12
   PubMed Web of Science ®Google Scholar
• National cancer institute, common toxicity criteria. Available from: http://ctep.cancer.gov/protocoldevelopment/electronic_ applications/docs/ctcaev3.pdf
   Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7(3):177-88
   PubMedGoogle Scholar
• Abdel-Rahman O, Fouad M. Everolimus-based combination for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): biological rationale and critical review of published data. Tumor Biol 2015;36(2):467-78
   Google Scholar
• Maass N, Harbeck N, Mundhenke C, et al. Everolimus as treatment for breast cancer patients with bone metastases only: results of the phase II RADAR study. J Cancer Res Clin Oncol 2013;139(12):2047-56
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of Everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. Cancer 2010;116(18):4256-65
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman O. Risk of mucocutaneous toxicities in patients with solid tumors treated with everolimus; a systematic review and meta-analysis. Expert Rev Anti Ther 2014;14(12):1529-36
   PubMed Web of Science ®Google Scholar
• Albiges L, Bergmann L, Eymard JC, et al. Everolimus for patients with metastatic renal cell carcinoma (mRCC) refractory to anti-VEGF therapy: preliminary results of a pooled analysis of noninterventional studies. J Clin Oncol 2013;31(6
   Google Scholar
• Ferté C, Paci A, Zizi M, et al. Natural history, management and pharmacokinetics of everolimus-induced-oral ulcers: insights into compliance issues. Eur J Cancer 2011;47(15):2249-55
   Google Scholar
• Sonis S, Treister N, Chawla S, et al. Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients. Cancer 2010;116(1):210-15
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman O, Fouad M. Risk of fatigue in patients with solid tumors treated with everolimus, temsirolimus or ridaforolimus: a comparative meta-analysis. Expert Rev Anti Ther 2015;15(4):477-86
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman O, Fouad M. Risk of fatigue and hepatic and metabolic toxicities in patients with solid tumors treated with everolimus: a meta-analysis. Future Oncol 2015;11(1):79-90
   PubMed Web of Science ®Google Scholar
• Gruenwald V, Weikert S, Pavel ME, et al. Practical management of everolimus-related toxicities in patients with advanced solid tumors. Onkologie 2013;36(5):295-302
   PubMed Web of Science ®Google Scholar
• Nicolatou-Galitis O, Nikolaidi A, Athanassiadis I, et al. Oral ulcers in patients with advanced breast cancer receiving everolimus: a case series report on clinical presentation and management. Oral Surg Oral Med Oral Pathol Oral Radiol 2013;116(2):e110-16
   PubMed Web of Science ®Google Scholar
• de Oliveira MA, Martins e Martins F, Wang Q, et al. Clinical presentation and management of mTOR inhibitor-associated stomatitis. Oral Oncol 2011;47(10):998-1003
   PubMed Web of Science ®Google Scholar
• Rugo HS, Pritchard KI, Gnant M, et al. Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2. Ann Oncol 2014;25(4):808-15
   PubMed Web of Science ®Google Scholar
• Hoff PM, Saragiotto DF, Barrios CH, et al. Randomized phase III trial exploring the use of long-acting release octreotide in the prevention of chemotherapy-induced diarrhea in patients with colorectal cancer: The LARCID trial. J Clin Oncol 2014;32(10):1006-11
   Google Scholar
• Huober J, Fasching PA, Hanusch C, et al. Neoadjuvant chemotherapy with paclitaxel and Everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide [EC] ± bevacizumab - results of the randomised GeparQuinto study [GBG 44]. Eur J Cancer 2013;49(10):2284-93
   PubMed Web of Science ®Google Scholar
• Franz DN, Belousova E, Sparagana S, et al. Efficacy and safety of Everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex [EXIST-1]: a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 2013;381(9861):125-32
   PubMed Web of Science ®Google Scholar
• Rini BI, Bellmunt J, Clancy J, et al. Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial. J Clin Oncol 2014;32(8):752-9
   PubMed Web of Science ®Google Scholar
• Bissler JJ, Kingswood JC, Radzikowska E, et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis [EXIST-2]: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2013;381(9869):817-24
   PubMed Web of Science ®Google Scholar
• Bachelot T, Bourgier C, Cropet C, et al. Randomized phase II trial of Everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol 2012;30(22):2718-24
   PubMed Web of Science ®Google Scholar
• Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012;366(6):520-9
   PubMed Web of Science ®Google Scholar
• Wolff AC, Lazar AA, Bondarenko I, et al. Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer. J Clin Oncol 2013;31(2):195-202
   PubMed Web of Science ®Google Scholar
• Ohtsu A, Ajani JA, Bai YX, et al. Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study. J Clin Oncol 2013;31(31):3935-43
   PubMed Web of Science ®Google Scholar
• André F, O’Regan R, Ozguroglu M, et al. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer [BOLERO-3]: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 2014;15(6):580-91
   PubMed Web of Science ®Google Scholar
• Zhu AX, Kudo M, Assenat E, et al. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: The EVOLVE-1 randomized clinical trial. JAMA 2014;312(1):57-67
   PubMed Web of Science ®Google Scholar
• Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011;364(6):514-23
   PubMed Web of Science ®Google Scholar
• Hess G, Herbrecht R, Romaguera J, et al. Phase III study to evaluate temsirolimus compared with investigator’s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009;27(23):3822-9
   PubMed Web of Science ®Google Scholar
• Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356(22):2271-81
   PubMed Web of Science ®Google Scholar
• Demetri GD, Chawla SP, Ray-Coquard I, et al. Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy. J Clin Oncol 2013;31(19):2485-92
   PubMed Web of Science ®Google Scholar
• Miracle mouthwash plus hydrocortisone vs prednisolone mouth rinse for mouth sores caused by everolimus. Available from: https://clinicaltrials.gov/ct2/show/NCT02229136
   Google Scholar
• Open-label, Phase II study of stomatitis prevention with a steroid-based mouthwash in post-menopausal women with ER+, HER2- metastatic or locally advanced breast cancer. Available from: https://clinicaltrials.gov/ct2/show/NCT02069093
   Google Scholar
• Caphosol in oral mucositis due to targeted therapy (COMTT). Available from: https://clinicaltrials.gov/ct2/show/NCT01265810
   Google Scholar
• Baselga J, Semiglazov V, van Dam P, et al. Phase II randomized study of neoadjuvant Everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 2009;27(16):2630-7
   PubMed Web of Science ®Google Scholar
• Pavel ME, Hainsworth JD, Baudin E, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome [RADIANT-2]: a randomised, placebo-controlled, phase III study. Lancet 2011;378(9808):2005-12
   PubMed Web of Science ®Google Scholar